Article ID Journal Published Year Pages File Type
3936243 Fertility and Sterility 2010 6 Pages PDF
Abstract
When using recombinant hCG microdose supplementation for controlled ovarian stimulation (COS), there are no differences in laboratory or clinical outcomes with the use of either GnRH antagonist or agonist for pituitary suppression.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary supp
Authors
, , , , , , , , , ,